Long-Term Consequences of Myelofibrosis and the Impact of Early Intervention

Myelofibrosis carries significant long-term consequences driven by progressive marrow failure, chronic inflammation, and organ involvement. Patients may experience worsening cytopenias, symptomatic splenomegaly, metabolic changes, and, in some cases, progression to acute leukemia. Early diagnosis and timely treatment help slow disease progression, reduce symptom burden, and maintain functional status, ultimately improving long-term quality of life. Blood transfusions are common as anemia advances and can provide important short-term relief from fatigue and dyspnea. However, they have limitations, including temporary benefit, iron overload, and the logistical burden of frequent clinic visits. For many patients and caregivers, ongoing transfusion needs can disrupt daily life and add emotional and financial strain. These factors underscore the importance of early, proactive management strategies that aim to reduce transfusion dependence and preserve overall well-being.